Presentatie van mw. drs. Mijnke Janssen op het Voorjaarscongres psychiatrie van de NVvP in 2016 over de uitkomsten van het onderzoek rond het Tornadoprogramma naar diagnostiek van ongecompliceerde ADHD binnen Karakter.
Presentatie van mw. drs. Mijnke Janssen op het Voorjaarscongres psychiatrie van de NVvP in 2016 over de uitkomsten van het onderzoek rond het Tornadoprogramma naar diagnostiek van ongecompliceerde ADHD binnen Karakter.
This document discusses how micro and nanotechnologies can contribute to progress in neuroscience. It describes how technologies like MOS transistors and nanoionics/nanoelectronics can help study the structure and function of synapses at the nanoscale level. Potential applications include using these technologies to better understand basic neuroscience, as well as in clinical areas like neuronal regeneration, neuroprotection, neuromodulation, and high resolution imaging. The document advocates for an interdisciplinary approach involving neurobiologists, neurologists, engineers, and materials scientists to identify potential applications and focus technology development efforts in order to maximize the impact of these technologies and further progress in understanding the brain.
The document discusses NERF and introduces Jo Bury as the managing director of VIB. In a single sentence summary, it states that NERF is led by Jo Bury, who is the managing director of VIB.
IMEC is a non-profit research organization established in 1984 by the Flemish government in Belgium with an initial investment of 62 million euros and about 70 staff. It has grown significantly over the years to have an annual budget of over 246 million euros and over 1650 staff from over 55 nationalities in 2008. IMEC focuses on microelectronics research and collaborates with over 600 industry and academic partners worldwide. Its areas of research include neuro-electronics, bioelectronics, nanotechnology and more with the goal of advancing healthcare technologies.
An interview on the potential and challenges of personalized medicine, published in Medisch Contact (a monthy journal for healthcare professionals). In Dutch.
This document discusses how micro and nanotechnologies can contribute to progress in neuroscience. It describes how technologies like MOS transistors and nanoionics/nanoelectronics can help study the structure and function of synapses at the nanoscale level. Potential applications include using these technologies to better understand basic neuroscience, as well as in clinical areas like neuronal regeneration, neuroprotection, neuromodulation, and high resolution imaging. The document advocates for an interdisciplinary approach involving neurobiologists, neurologists, engineers, and materials scientists to identify potential applications and focus technology development efforts in order to maximize the impact of these technologies and further progress in understanding the brain.
The document discusses NERF and introduces Jo Bury as the managing director of VIB. In a single sentence summary, it states that NERF is led by Jo Bury, who is the managing director of VIB.
IMEC is a non-profit research organization established in 1984 by the Flemish government in Belgium with an initial investment of 62 million euros and about 70 staff. It has grown significantly over the years to have an annual budget of over 246 million euros and over 1650 staff from over 55 nationalities in 2008. IMEC focuses on microelectronics research and collaborates with over 600 industry and academic partners worldwide. Its areas of research include neuro-electronics, bioelectronics, nanotechnology and more with the goal of advancing healthcare technologies.
An interview on the potential and challenges of personalized medicine, published in Medisch Contact (a monthy journal for healthcare professionals). In Dutch.
De presentatie belicht de eenheid voor translationeel borstkankeronderzoek van de groep ziekenhuizen "Gasthuiszusters van Antwerpen" en werd gemaakt in het kader van een kunstveiling waarvan de opbrengst een deel van het onderzoeksprogramma zal steunen.
2. De brug tussen onderzoek en
patiёnt
• Panelgesprek met:
– Prof. Bouillon, Intensieve geneeskunde
K.U.Leuven
– Prof. Christine Van Broeckhoven, Moleculaire
Genetica UA
– Prof. Marc Noppen, UZ Brussel
– Prof. Francis Colardyn, UZ Gent
– Dr. Staf Van Reet, Movetis
– Désiré Collen, Thrombogenics
• Moderator: Ann Van Gysel, FlandersBio
3. De gezondheidszorg vandaag
• Sterke vooruitgang in biomedisch onderzoek
– Nieuwe opties voor betere diagnose, preventie
en behandeling
– Testen van deze hypotheses
4. De gezondheidszorg vandaag
• Uitgaven stijgen sneller dan inkomsten
– Meer efficiёnte behandelingen
• Biofarma belangrijke innovator en R&D
investeerder
– Valorisatie van de onderzoeksinspanningen
5. De brug tussen onderzoek en
patiёnt
Translationeel
onderzoek
Onderzoek
Betere
diagnose en
behandelingen
6. De brug tussen onderzoek en
patiёnt
Translationeel
onderzoek
Onderzoek
Betere
diagnose en
behandelingen
7. De brug tussen onderzoek en
patiёnt
Translationeel
onderzoek
Onderzoek
Betere
diagnose en
behandelingen
8. De brug tussen onderzoek en
patiёnt
Translationeel
onderzoek
Academische
Onderzoek spelers en
industrie
Betere
diagnose en Patiёnt
behandelingen
9. De brug tussen onderzoek en
patiёnt
• Panelgesprek met:
– Prof. Bouillon, Intensieve geneeskunde
K.U.Leuven
– Prof. Christine Van Broeckhoven, Moleculaire
Genetica UA
– Prof. Marc Noppen, UZ Brussel
– Prof. Francis Colardyn, UZ Gent
– Dr. Staf Van Reet, Movetis
– Désiré Collen, Thrombogenics
• Moderator: Ann Van Gysel, FlandersBio
